AROA BIOSURGERY LIMITED Financials Aroa Biosurgery Limited
Equities
ARX
NZARXE0001S1
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.555 AUD | -2.63% |
|
+13.27% | -33.13% |
| May. 21 | Transcript : Aroa Biosurgery Limited, 2024 Earnings Call, May 21, 2024 | |
| May. 21 | Aroa Biosurgery Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 392.4 | 286.6 | 384.7 | 206.7 | - | - |
| Enterprise Value (EV) 1 | 373.3 | 235.1 | 345.8 | 178.7 | 178.1 | 174.6 |
| P/E ratio | -20.4 x | -34.2 x | -934 x | -19.6 x | -953 x | 21.3 x |
| Yield | - | - | - | - | - | 0.55% |
| Capitalization / Revenue | 17.6 x | 7.22 x | 6.07 x | 3.02 x | 2.41 x | 1.92 x |
| EV / Revenue | 16.7 x | 5.92 x | 5.46 x | 2.59 x | 2.08 x | 1.63 x |
| EV / EBITDA | -83 x | -157 x | 224 x | -57.8 x | 32.5 x | 11.2 x |
| EV / FCF | -59.5 x | -14.7 x | -35.3 x | -16.4 x | -31.2 x | 20.4 x |
| FCF Yield | -1.68% | -6.8% | -2.83% | -6.1% | -3.2% | 4.9% |
| Price to Book | 6.71 x | 2.85 x | 3.78 x | 2.19 x | 2.14 x | 1.92 x |
| Nbr of stocks (in thousands) | 300,726 | 342,461 | 343,109 | 344,208 | - | - |
| Reference price 2 | 1.305 | 0.8370 | 1.121 | 0.6005 | 0.6005 | 0.6005 |
| Announcement Date | 5/24/21 | 5/23/22 | 5/30/23 | 5/20/24 | - | - |
1NZD in Million2NZD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 22.34 | 39.68 | 63.36 | 69.07 | 85.73 | 107.4 |
| EBITDA 1 | -4.498 | -1.497 | 1.542 | -3.095 | 5.478 | 15.63 |
| EBIT 1 | -6.361 | -4.628 | -2.292 | -7.49 | 0.1124 | 10.66 |
| Operating Margin | -28.47% | -11.66% | -3.62% | -10.84% | 0.13% | 9.92% |
| Earnings before Tax (EBT) 1 | -19.1 | -8.261 | -0.384 | -10.43 | 0.2748 | 12.17 |
| Net income 1 | -19.21 | -8.386 | -0.396 | -10.63 | -0.1532 | 9.732 |
| Net margin | -85.98% | -21.13% | -0.62% | -15.39% | -0.18% | 9.06% |
| EPS 2 | -0.0639 | -0.0245 | -0.001200 | -0.0309 | -0.000630 | 0.0282 |
| Free Cash Flow 1 | -6.272 | -15.98 | -9.801 | -10.9 | -5.7 | 8.55 |
| FCF margin | -28.07% | -40.26% | -15.47% | -15.78% | -6.65% | 7.96% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 54.71% |
| FCF Conversion (Net income) | - | - | - | - | - | 87.85% |
| Dividend per Share 2 | - | - | - | - | - | 0.003330 |
| Announcement Date | 5/24/21 | 5/23/22 | 5/30/23 | 5/20/24 | - | - |
1NZD in Million2NZD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 | 2026 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.18 | 13.16 | 17.85 | 21.83 | 29.34 | 34.02 | 31.87 | 37.2 | 40.28 | 44.6 | 47.05 |
| EBITDA 1 | -2.316 | -2.182 | -1.156 | -0.341 | 1.319 | 0.223 | -2.667 | -0.428 | -0.683 | 4.548 | - |
| EBIT 1 | -3.45 | -2.911 | -2.702 | -1.926 | -0.525 | -1.767 | -4.806 | -2.684 | -2.635 | 3.426 | - |
| Operating Margin | -37.58% | -22.12% | -15.14% | -8.82% | -1.79% | -5.19% | -15.08% | -7.22% | -6.54% | 7.68% | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/25/20 | 5/24/21 | 11/24/21 | 5/23/22 | 11/28/22 | 5/30/23 | 11/27/23 | 5/20/24 | - | - | - |
1NZD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 19.1 | 51.5 | 38.8 | 29.5 | 28.6 | 32.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -6.27 | -16 | -9.8 | -10.9 | -5.7 | 8.55 |
| ROE (net income / shareholders' equity) | -22.9% | -6.76% | -0.39% | -10.8% | 0.34% | 9.86% |
| ROA (Net income/ Total Assets) | - | -8.72% | -0.35% | -9.34% | 0.11% | 9.9% |
| Assets 1 | - | 96.16 | 114.6 | 113.8 | -138.6 | 98.3 |
| Book Value Per Share 2 | 0.1900 | 0.2900 | 0.3000 | 0.2800 | 0.2800 | 0.3100 |
| Cash Flow per Share 2 | -0.0200 | -0.0300 | -0.0100 | -0.0200 | 0.0100 | 0.0300 |
| Capex 1 | 1.27 | 4.46 | 6.03 | 3.52 | 3.17 | 3.53 |
| Capex / Sales | 5.66% | 11.23% | 9.52% | 5.1% | 3.69% | 3.29% |
| Announcement Date | 5/24/21 | 5/23/22 | 5/30/23 | 5/20/24 | - | - |
1NZD in Million2NZD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.6005
NZD
Average target price
1.077
NZD
Spread / Average Target
+79.33%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.13% | 130M | |
| +4.53% | 26.97B | |
| -40.08% | 2.67B | |
| -21.07% | 2.4B | |
| +16.30% | 2.28B | |
| +8.60% | 2.24B | |
| -13.37% | 1.82B | |
| +24.48% | 1.26B | |
| -1.10% | 1.21B | |
| +20.00% | 1.2B |
- Stock Market
- Equities
- ARX Stock
- Financials Aroa Biosurgery Limited
